Stay updated with breaking news from Inborn Errors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FBX-101 clinical data demonstrating safety and initial efficacy from the RESKUE trial is being presented at the 2022 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the six treated patients The five longest treated patients exhibited elevated a-Gal A activity
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AUSTIN, Texas, Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new ...
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to...